B
Bull
Bull · 25%IMCC
$3.63
Precio del escenario
$3.410
-0.459 (-13.45%)Al cierre
Loading chart…
- High
- 3.900
- Open
- 3.890
- VWAP
- 3.57
- Vol
- 76.45K
- Mkt Cap
- 6.03M
- Low
- 3.400
- Amount
- 272.92K
- EV/EBITDA, TTM
- -0.65
IM Cannabis Corp. is an international cannabis company that provides cannabis products to medical patients in Israel and Germany. The Company's ecosystem operates in Israel through its subsidiaries, which import and distribute cannabis to medical patients, leveraging years of proprietary data and patient insights. The Company also operates medical cannabis retail pharmacies, online platforms, distribution centers, and logistical hubs in Israel that enable the safe delivery and quality control of its products throughout the entire value chain. In Germany, the Company’s ecosystem operates through Adjupharm GmbH, where it distributes cannabis to pharmacies for medical cannabis patients. The Company's brands include The Craft Collection, The Top-Shelf Collection, The Signature Collection, The Full Spectrum Extracts, Roma, The WAGNERS, BLKMKT, LOT420, The PICO collection, and Flower.
AI analysis of IM Cannabis Corp (IMCC)
sellIM Cannabis Corp is not a good buy right now due to its current price of $3.41, a year-to-date change of -92.37%, and ongoing financial losses. The company's gross margin has dropped to 19.83% in Q2 2026, indicating declining profitability. Additionally, the stock is under pressure from Nasdaq compliance issues, which could further impact its liquidity and market perception.
Métricas de valoración
The current forward P/E ratio for IM Cannabis Corp (IMCC) is 42.37, compared to its 5-year average forward P/E of -26.30.
Alphio AI Price Scenarios for IMCC
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Cronología de eventos
Noticias
8.508-19NASDAQ.COMIM Cannabis Announces 30-for-1 Share Consolidation to Meet Nasdaq Compliance
8.508-18PRnewswireIM Cannabis Announces Share Consolidation Plan
8.508-18NewsfilterIM Cannabis Corp. Approves Share Consolidation to Regain Nasdaq Compliance
8.508-17PRnewswireIM Cannabis Corp. Finalizes Share Purchase Agreement to Enhance Equity
9.508-13PRnewswireIM Cannabis Reports Financial Results for Q2 2026
IMCC FAQ — answered by Alphio AI
IM Cannabis Corp. is an international cannabis company that provides cannabis products to medical patients in Israel and Germany. The Company's ecosystem operates in Israel through its subsidiaries, which import and distribute cannabis to medical patients, leveraging years of proprietary data and patient insights. The Company also operates medical cannabis retail pharmacies, online platforms, distribution centers, and logistical hubs in Israel that enable the safe delivery and quality control of its products throughout the entire value chain. In Germany, the Company’s ecosystem operates through Adjupharm GmbH, where it distributes cannabis to pharmacies for medical cannabis patients. The Company's brands include The Craft Collection, The Top-Shelf Collection, The Signature Collection, The Full Spectrum Extracts, Roma, The WAGNERS, BLKMKT, LOT420, The PICO collection, and Flower. It operates in the Consumer Non-Cyclicals sector (MEDICINAL CHEMICALS AND BOTANICAL PRODUCTS industry).
IM Cannabis Corp is not a good buy right now due to its current price of $3.41, a year-to-date change of -92.37%, and ongoing financial losses. The company's gross margin has dropped to 19.83% in Q2 2026, indicating declining profitability. Additionally, the stock is under pressure from Nasdaq compliance issues, which could further impact its liquidity and market perception.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.